新型αvβ3和Neuropilin-1双靶点正电子成像探针<sup>18</sup>F-FAl-NOTA-RGD-ATWLPPR用于脑胶质瘤的PET显像研究

赵龙; 罗作明; 孙龙; 吴华; 陈皓鋆; 赵龙; 罗作明; 孙龙; 吴华; 陈皓鋆

doi:10.3760/cma.j.issn.1673-4114.2017.04.001

[1]

Wu H, Chen H, Sun Y, et al. Imaging integrin αvβ3 positive glioma with a novel RGD dimer probe and the impact of antiangiogenic agent(Endostar) on its tumor uptake[J]. Cancer Lett, 2013, 335(1) 75-80. DOI:10.1016/j.canlet.2013.01.053.

[2]

Chen H, Niu G, Wu H, et al. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3[J]. Theranostics, 2016, 6(1):78-92. DOI:10.7150/thno.13242.

[3]

Miyauchi JT, Chen D, Choi M, et al. Ablation of neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression[J]. Oncotarget, 2016, 7(9):9801-9814. DOI:10.18632/oncotarget.6877.

[4]

Tuszynski GP, Knight LC, Kornecki E, et al. Labeling of platelet surface proteins with ¹²⁵I by the iodogen method[J]. Anal Biochem, 1983, 130:166-170. DOI:10.1016/0003-2697(83)90664-4.

[5]

Capello A, Krenning EP, Bernard BF, et al. Anticancer activity of targeted proapoptotic peptides[J]. J Nucl Med, 2006, 47(1):122-129. DOI:10.1158/1535-7163.

[6]

Liu Z, Yan Y, Chin FT, et al. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using ¹⁸F-labeled PEGylated RGD-bombesin heterodimer ¹⁸F-FB-PEG3-Glu-RGD-BBN[J]. J Med Chem, 2009, 52(2):425-432. DOI:10.1021/jm801285t.

[7]

Liu SL, Liu HG, Jiang H, et al. One-step radiosynthesis of ¹⁸F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging[J]. Eur J Nucl Med Mol Imaging, 2011, 38(9):1732-1741. DOI:10.1007/s00259-011-1847-4.

[8]

Zhang J, Niu G, Lang L, et al. Clinical translation of a dual integrin αvβ3-and Gastrin-Releasing peptide Receptor-Targeting PET radiotracer, ⁶⁸Ga-BBN-RGD[J]. J Nucl Med, 2017, 58(2):228-234. DOI:10.2967/jnumed.116.177048.

[9]

Chen Q, Ma Q, Chen M, et al. An exploratory study on ^99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to ^99mTc-3P4-RGD2[J/OL]. PLoS One, 2015, 10(4):e0123401[2017-03-08]. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123401. DOI:10.1371/journal.pone.0123401.

[10]

Fan D, Zhang X, Zhong L, et al. ⁶⁸Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma[J]. Bioconjug Chem, 2015, 26(6):1054-1060. DOI:10.1021/acs.bioconjchem.5b00169.

[11]

Yan Y, Chen K, Yang M, et al. A new ¹⁸F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging[J]. Amino Acids, 2011, 41(2):439-447. DOI:10.1007/s00726-010-0762-5.

[12]

Yan Y, Chen X. Peptide heterodimers for molecular imaging[J].Amino Acids, 2011, 41(5):1081-1092. DOI:10.1007/s00726-010-0546-y.

[13]

Liu Z, Huang J, Dong C, et al. ^99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma[J]. Mol Pharm, 2012, 9(5):1409-1417. DOI:10.1021/mp200661t.

[14]

Liu Z, Niu G, Shi J, et al. ⁶⁸Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers:promising agents for tumor integrin αvβ3 PET imaging[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6):947-957. DOI:10.1007/s00259-008-1045-1.

[15]

Jin X, Liang N, Wang M, et al. Integrin imaging with ^99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from Non-Small cell lung cancer[J]. Radiology, 2016, 281(3):958-966. DOI:10.1148/radiol.2016150813.